Neurodegenerative diseases are one of the major challenges for health care systems in the ageing societies of the Western World, with currently over 6 million people affected in the European Union and 44.4 million people worldwide. This number will likely double over the next 20 years due to the ageing population. The most common cause of dementia is Alzheimer’s disease (AD), which represents about 70 % of all cases. However, according to epidemiological data, only half of the patients suffering from AD are currently identified, and then often only in the advanced stages of the disease. It is suspected that one of the main reasons for this is the lack of accuracy of diagnostic assays used for identification and quantification of relevant biomarkers. It has been demonstrated that in the prodromal stage of AD the accuracy of single biomarkers is only about 85 % leading to a considerable amount of false positive/negative diagnoses.
The aim of the EMPIR project 15HLT02 ReMiND was, therefore, to develop potential reference measurement procedures for current and potential biomarkers for the diagnosis of AD. The project ReMiND 15HLT02 has received funding from the EMPIR programme co-financed by the Participating States and from the European Union’s Horizon 2020 research and innovation programme between July 2016 to June 2019. Further inforamtion can also be found on the 
EURAMET website.